Skip to content

HuVePharma

Active
Public limited companyfounded 200521 yrs activeUitbreidingstraat 80, 2600 Antwerpen, BelgiumKBO/BCE: BE 0875.283.062

HuVePharma has been active since 2005 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €43.89M and a net result of €4.78M. Equity is growing by ~14.5% per year across the filed fiscal years. Its solvency ranks better than 54% of 6007 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.3% (very low).

Checked score

Score 2024
87 / 100
Excellent▲ +8 vs 2023
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2023
Profitability61▼-2
Solvency68▼-4
Growth70▲+2
Stability100
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2M at 30 days acceptable
Liquidity tight (current ratio 1.01 against 1.08 in 2023), and 55% of the assets are financed with debt.
Credit advice for your own amount and term

Signals

Six signals. The signal on the left, the evidence on the right.
lowers risk+raises riskneutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
elevated failure risk from 2 to 8 years 21 years 0 30 y
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2024
Solvency, return and age of the figures
Solvency
45%
Return on assets
4.9%
Age of the figures
20 mo
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 46
Relative position
BE, all sectors
reference
Sector 46
higher
← fewer bankruptcies more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 14-06-2025, 47 days ahead of the deadline.
NBB · 5 filings
Deviation from the deadline
2025
not confirmed
2024
47 d early
2023
37 d early
2022
56 d early
2021
40 d early
2020
65 d early
← before the deadline after the deadline →
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

Financials · fiscal year 2024, full schema, statutory

Turnover
€115.03M▲ 14.7%
2023 · €100.30M
2018: €79.81M 2019: €79.07M 2020: €92.19M 2021: €95.48M 2022: €100.70M 2023: €100.30M
2018 → 2024
EBIT margin
6.0%▼ 0.3pp
2023 · 6.3%
2018: 6.7% 2019: 6.5% 2020: 6.2% 2021: 6.8% 2022: 6.4% 2023: 6.3%
2018 → 2024
Net result
€4.78M▲ 11.4%
2023 · €4.29M
2018: €3.14M 2019: €3.48M 2020: €4.25M 2021: €4.75M 2022: €4.34M 2023: €4.29M
2018 → 2024
Working capital
€666k▼ 77.9%
2023 · €3.02M
2018: €-12.42M 2019: €-12.10M 2020: €-10.43M 2021: €-7.56M 2022: €-193k 2023: €3.02M
2018 → 2024
Multi-year overview
Every figure with its change against the year before
▲ rise ▼ fall
Line20202021202220232024Trend
Turnover€92.19M-€95.48M▲ 3.6%€100.70M▲ 5.5%€100.30M▼ 0.4%€115.03M▲ 14.7%
Equity€25.73M-€30.48M▲ 18.5%€34.82M▲ 14.2%€39.11M▲ 12.3%€43.89M▲ 12.2%
Operating result€5.76M-€6.53M▲ 13.4%€6.44M▼ 1.4%€6.30M▼ 2.2%€6.84M▲ 8.7%
Net result€4.25M-€4.75M▲ 11.8%€4.34M▼ 8.6%€4.29M▼ 1.2%€4.78M▲ 11.4%
Result per fiscal year
Operating resultNet result
€0€2.00M€4.00M€6.00MOperating result 2020: €5.76M€5.76MNet result 2020: €4.25M€4.25MOperating result 2021: €6.53M€6.53MNet result 2021: €4.75M€4.75MOperating result 2022: €6.44M€6.44MNet result 2022: €4.34M€4.34MOperating result 2023: €6.30M€6.30MNet result 2023: €4.29M€4.29MOperating result 2024: €6.84M€6.84MNet result 2024: €4.78M€4.78M20202021202220232024
The operating result recovers in 2024; 2024 is 9% above 2023 and is the highest year so far.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €97.54M
Fixed assets €48.73M▲ 17.1%
Current assets €48.81M▲ 19.0%
Equity and liabilities €97.54M
Equity €43.89M▲ 12.2%
Debt €53.65M▲ 23.2%
The debt ratio rises from 52.7% to 55.0%: debt grows faster than equity.
Key figures and ratios
2024 value · change against 2023
EBITDA
€18.92M
2023 · €17.83M
Cash flow
€16.85M
2023 · €15.82M
Solvency
45.0%
2023 · 47.3%
Current ratio
1.01
2023 · 1.08
Quick ratio
0.46
2023 · 0.50
Debt / equity
1.22
2023 · 1.11
ROE
10.9%
2023 · 11.0%
ROA
4.9%
2023 · 5.2%
Interest coverage
180.86
2023 · 203.50
Debt
€53.65M
2023 · €43.54M
Debt ≤ 1 year
€48.14M
2023 · €38.00M
Debt > 1 year
€87k
2023 · €126k
Income taxes
€1.49M
2023 · €1.43M
Staff costs
€11.99M
2023 · €11.89M
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2024 against 2023
Balance sheet Code20232024
Assets
Total assets20/58€82.65M€97.54M
Fixed assets21/28€41.63M€48.73M
Intangible fixed assets21€40.57M€47.62M
Tangible fixed assets22/27€804k€829k
Plant, machinery and equipment23€283k€234k
Furniture and vehicles24€156k€143k
Other tangible fixed assets26€365k€452k
Financial fixed assets28€260k€289k
Affiliated companies280/1€1k€1k=
Participating interests280€1k€1k=
Other financial fixed assets284/8€259k€288k
Amounts receivable and cash guarantees285/8€259k€288k
Current assets29/58€41.02M€48.81M
Amounts receivable after more than one year29€7k€5k
Other amounts receivable291€7k€5k
Stocks and contracts in progress3€22.20M€26.48M
Stocks30/36€22.20M€26.48M
Goods purchased for resale34€22.20M€26.48M
Amounts receivable within one year40/41€12.74M€14.55M
Trade receivables40€11.97M€13.34M
Other amounts receivable41€769k€1.21M
Current investments50/53€18k€18k=
Other investments51/53€18k€18k=
Cash at bank and in hand54/58€4.36M€5.80M
Deferred charges and accrued income490/1€1.70M€1.96M
Equity and liabilities
Total equity and liabilities10/49€82.65M€97.54M
Equity10/15€39.11M€43.89M
Contributions10/11€4.50M€4.50M=
Capital10€4.50M€4.50M=
Issued capital100€4.50M€4.50M=
Reserves13€11.88M€12.86M
Non-distributable reserves130/1€450k€450k=
Legal reserve130€450k€450k=
Tax-exempt reserves132€4.25M€5.24M
Distributable reserves133€7.17M€7.17M=
Profit (loss) carried forward14€22.73M€26.52M
Amounts payable17/49€43.54M€53.65M
Amounts payable after more than one year17€126k€87k
Financial debts170/4€126k€87k
Leasing and similar obligations172€126k€87k
Amounts payable within one year42/48€38.00M€48.14M
Current portion of amounts payable after more than one year42€99k€99k
Trade debts44€35.81M€45.76M
Suppliers440/4€35.81M€45.76M
Advances received on contracts in progress46-€90k
Taxes, remuneration and social security45€2.09M€2.08M
Taxes450/3€1.11M€1.13M
Remuneration and social security454/9€975k€944k
Other amounts payable47/48-€118k
Accrued charges and deferred income492/3€5.42M€5.43M
Income statement Code20232024
Operating income70/76A€133.93M€152.59M
Turnover70€100.30M€115.03M
Own construction capitalised72€2.71M€3.13M
Other operating income74€30.92M€34.43M
Operating charges60/66A€127.63M€145.75M
Goods for resale, raw materials and consumables60€76.89M€90.73M
Purchases600/8€74.38M€95.01M
Change in stocks: decrease (increase)609€2.50M€-4.28M
Services and other goods61€26.73M€30.35M
Remuneration, social security and pensions62€11.89M€11.99M
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€11.53M€12.07M
Other operating charges640/8€537k€605k
Non-recurring operating charges66A€60k€1k
Operating profit (loss)9901€6.30M€6.84M
Financial income75/76B€403k€371k
Recurring financial income75€403k€371k
Income from current assets751€21k€58k
Other financial income752/9€382k€313k
Non-recurring financial income76B€98-
Financial charges65/66B€983k€946k
Recurring financial charges65€983k€946k
Debt charges650€88k€105k
Other financial charges652/9€895k€842k
Profit (loss) for the period before taxes9903€5.72M€6.27M
Income taxes67/77€1.43M€1.49M
Taxes670/3€1.43M€1.51M
Tax adjustments and reversals of tax provisions77-€23k
Profit (loss) for the period9904€4.29M€4.78M
Transfer to tax-exempt reserves689€989k€989k=
Profit (loss) for the period to be appropriated9905€3.30M€3.79M
Appropriation of the result
Profit (loss) to be appropriated9906€22.73M€26.52M
Profit (loss) brought forward from the previous period14P€19.44M€22.73M
Social balance
Average headcount (FTE)908781.082.0

The notes to these accounts (81 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

2026
27-08
State Gazette act General meeting · Director resignation
General meeting · Director resignation · Director appointment13 facts ▸
  • General meeting, 2026-08-10
  • Director resignation, Eddy Piron (bestuurder)
  • Director appointment, Ramon Carlos Soriano Campistany (bestuurder)
  • Mandate compensation, Ramon Carlos Soriano Campistany
  • Director reappointment, Kiril Domuschiev (bestuurder)
  • Director reappointment, SDL Management BV (bestuurder)
  • Permanent representative, Sven Verbraeken
  • Board composition, bestuurder, 2026-09-01
  • Board composition, bestuurder, 2026-09-01
  • Board composition, bestuurder, 2026-09-01
  • Board meeting, 2026-08-10
  • Director resignation, Eddy Piron (gedelegeerd bestuurder)
  • +1 further facts in this act
2025
14-06
NBB filing Annual accounts filed
fiscal year 2024 · full schema
14-06
NBB filing Annual accounts filed
fiscal year 2024 · consolidated
2024
31-12
Financial Highest result since 2018net €4.78M ▲11.4%
Operating result €6.84M, net result €4.78M, both a record.
24-06
NBB filing Annual accounts filed
fiscal year 2023 · full schema
24-06
NBB filing Annual accounts filed
fiscal year 2023 · consolidated
2023
05-06
NBB filing Annual accounts filed
fiscal year 2022 · full schema
05-06
NBB filing Annual accounts filed
fiscal year 2022 · consolidated
2022
21-06
NBB filing Annual accounts filed
fiscal year 2021 · full schema
21-06
NBB filing Annual accounts filed
fiscal year 2021 · consolidated
2021
28-05
NBB filing Annual accounts filed
fiscal year 2020 · full schema
27-05
NBB filing Annual accounts filed
fiscal year 2020 · consolidated
2020
31-12
Financial Equity above €25MEq €25.73M ▲19.8%
3 profitable years in a row build equity to €25.73M.
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors
under verification, no change since 2026
This board is reconstructed from a single act (26108836). A Gazette act generally publishes only CHANGES, not a full roll call, so directors unchanged since then may be missing here. The KBO register holds the complete list of function holders.
Ramon Carlos Soriano Campistany
Director · since 01-09-2026
Current
Kiril Domuschiev
Director · since 10-08-2026
Current
SDL Management
Director · since 10-08-2026 · Private limited company · perm. rep.: Sven Verbraeken
Current
01-09-2026 Ramon Carlos Soriano Campistany: Appointed as Director
01-09-2026 Ramon Carlos Soriano Campistany: Appointed as Managing director
31-08-2026 Eddy Piron: Resigned as Director
31-08-2026 Eddy Piron: Resigned as Managing director
10-08-2026 Kiril Domuschiev: Mandate renewed as Director
10-08-2026 SDL Management: Mandate renewed as Director
Location & real-estate footprint
Registered office, Antwerpen · 1 establishment unit since 2005
establishment The establishment unit on the map
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Uitbreidingstraat 802600 Antwerpen
Ground area
9,631 m²
Building footprint
567 m²
Volume, LiDAR
13,029 m³
Parcel 11303B0445/00N008, Flanders · tallest building 28.2 m, ±8 floors. Linked by address, not a title deed.
1 establishment unit
HuVePharma
Uitbreidingstraat 80, 2600 AntwerpenAir transport
since 20052.148.211.686
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
11303B0445/00N008 Flanders 9,631 m² 1 · 567 m² 28.2 m · 8 fl.
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Structure & network

Ownership & control

1 party
Control over this companysits on this company's board1
1 subsidiary · 1 location
controls
HuVePharmaBE 0875.283.062

Recognitions · licences · registrations

Food safety, FASFC

1 site
Antwerpen2.148.211.686
4 permissions
Groothandelaar grondstoffen · since 01-02-2010
Toelating · Groothandelaar mengvoeders · since 01-02-2010
Erkenning · Groothandelaar additieven (erkenning) · since 11-08-2005
and 1 more

Legal Entity Identifier

9676001Z4UE03PFYXL52
live in the LEI register

Similar companies · same sector, comparable size

Of 688 companies in sector 46216 we hold annual accounts for 475. 55 are within a factor 10 of this equity.See the whole sector

Company data · Crossroads Bank

Identification
Legal formPublic limited company
Founded27-07-2005
Fiscal year end31-12
Activities, NACEBEL
46216Wholesale of agricultural produce and animal feed, general range
46389Wholesale of other food products
51210
51384
Sources
Crossroads Bank for EnterprisesNational Bank · 30 filingsAddress and cadastre registers

Data from official sources, last processed on 13-09-2026. Scores and ratios are computed by Checked and are not a credit decision.